First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila, Brittanie M Millang, Shweta S. Chavan, Carly Alterman, Joanne F. Chou, Michal Segal, Marc Simmons, Parisa Momtaz,

The Lancet Oncology · 2020 · 357 citations · 31 references

DOIFull text

Open access

Concepts

References

31